Literature DB >> 11456210

Developing guidance for budget impact analysis.

P Trueman1, M Drummond, J Hutton.   

Abstract

The role of economic evaluation in the efficient allocation of healthcare resources has been widely debated. Whilst economic evidence is undoubtedly useful to purchasers, it does not address the issue of affordability which is an increasing concern. Healthcare purchasers are concerned not just with maximising efficiency but also with the more simplistic goal of remaining within their annual budgets. These two objectives are not necessarily consistent. This paper examines the issue of affordability, the relationship between affordability and efficiency and builds the case for why there is a growing need for budget impact models to complement economic evaluation. Guidance currently available for such models is also examined and it is concluded that this guidance is currently insufficient. Some of these insufficiencies are addressed and some thoughts on what constitutes best practice in budget impact modelling are suggested. These suggestions include consideration of transparency, clarity of perspective, reliability of data sources, the relationship between intermediate and final end-points and rates of adoption of new therapies. They also include the impact of intervention by population subgroups or indications, reporting of results, probability of re-deploying resources, the time horizon, exploring uncertainty and sensitivity analysis, and decision-maker access to the model. Due to the nature of budget impact models, the paper does not deliver stringent methodological guidance on modelling. The intention was to provide some suggestions of best practice in addition to some foundations upon which future research can build.

Entities:  

Mesh:

Year:  2001        PMID: 11456210     DOI: 10.2165/00019053-200119060-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Drug coverage decisions: the role of dollars and values.

Authors:  K Titlow; L Randel; C M Clancy; E J Emanuel
Journal:  Health Aff (Millwood)       Date:  2000 Mar-Apr       Impact factor: 6.301

2.  Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK.

Authors:  D Monkman
Journal:  BMJ       Date:  2000-11-25

3.  Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach.

Authors:  D B Mather; S D Sullivan; D Augenstein; D S Fullerton; D Atherly
Journal:  Am J Manag Care       Date:  1999-03       Impact factor: 2.229

4.  Research into the use of health economics in decision making in the United Kingdom--Phase II. Is health economics 'for good or evil'?

Authors:  T Duthie; P Trueman; J Chancellor; L Diez
Journal:  Health Policy       Date:  1999-01       Impact factor: 2.980

5.  Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.

Authors:  P Primatesta; N R Poulter
Journal:  BMJ       Date:  2000-11-25

6.  PBMA (programme budgeting marginal analysis)--its role in the future purchasing arrangements for health care services.

Authors:  H Wilson; S Scott
Journal:  Health Policy       Date:  1995-08       Impact factor: 2.980

7.  Current trends in the use of pharmacoeconomics and outcomes research in europe.

Authors:  M Drummond; D Dubois; L Garattini; B Horisberger; B Jönsson; I S Kristiansen; C Le Pen; C G Pinto; P B Poulsen; J Rovira; F Rutten; M G von der Schulenburg; H Sintonen
Journal:  Value Health       Date:  1999 Sep-Oct       Impact factor: 5.725

8.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

9.  The use of statins: a case of misleading priorities?

Authors:  N Freemantle; R Barbour; R Johnson; M Marchment; A Kennedy
Journal:  BMJ       Date:  1997-10-04

10.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

View more
  42 in total

1.  A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.

Authors:  David L Veenstra; Scott D Ramsey; Sean D Sullivan
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Cost effectiveness analysis in health care: contraindications.

Authors:  Cam Donaldson; Gillian Currie; Craig Mitton
Journal:  BMJ       Date:  2002-10-19

3.  Coping with uncertainty on health decisions: assessing new solutions.

Authors:  Fernando Antoñanzas; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló
Journal:  Eur J Health Econ       Date:  2012-08

4.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes.

Authors:  Gianluca Baio; Pierluigi Russo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 6.  Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.

Authors:  Sanjoy Roy; S Suresh Madhavan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  Budget-impact analyses: a critical review of published studies.

Authors:  Ewa Orlewska; Laszlo Gulácsi
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.

Authors:  Krista A Payne; Gail Myhr
Journal:  Healthc Policy       Date:  2010-02

9.  Budget impact analysis in economic evaluation: a proposal for a clearer definition.

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2011-12

10.  Cost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients.

Authors:  Nicholas Graves; Mary Courtney; Helen Edwards; Anne Chang; Anthony Parker; Kathleen Finlayson
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.